Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Combination biologic therapy.

J D Isaacs1, A W Morgan, V Strand

  • 1Department of Rheumatology, University of Leeds, UK. rrrjdi@leeds.ac.uk

Clinical and Experimental Rheumatology
|December 10, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pretreatment absolute monocyte counts are associated with biological disease-modifying anti-rheumatic drug non-response in patients with rheumatoid arthritis.

Scandinavian journal of rheumatology·2025
Same author

Genetic proxies for clinical traits are associated with increased risk of severe COVID-19.

Scientific reports·2025
Same author

Oral 11β-HSD1 inhibitor AZD4017 improves wound healing and skin integrity in adults with type 2 diabetes mellitus: a pilot randomized controlled trial.

European journal of endocrinology·2022
Same author

TRAFIC: statistical design and analysis plan for a pragmatic early phase 1/2 Bayesian adaptive dose escalation trial in rheumatoid arthritis.

Trials·2021
Same author

Unmet needs in ankylosing spondylitis patients receiving tumour necrosis factor inhibitor therapy; results from a large multinational real-world study.

BMC rheumatology·2020
Same author

Standardized protocols for differentiation of THP-1 cells to macrophages with distinct M(IFNγ+LPS), M(IL-4) and M(IL-10) phenotypes.

Journal of immunological methods·2020
Same journal

The expanded cardiovascular risk prediction score as a cardiovascular mortality predictor in rheumatoid arthritis.

Clinical and experimental rheumatology·2026
Same journal

Rising overweight and obesity in Swiss psoriatic arthritis patients, 2007-2022: a nationwide registry-population comparison.

Clinical and experimental rheumatology·2026
Same journal

Clinical features and gastrointestinal bleeding risk factors in IgA vasculitis patients: a retrospective study in a large volume centre.

Clinical and experimental rheumatology·2026
Same journal

Reply to the comment on: The microbiota in axial spondyloarthritis: what have we learned from Mendelian randomisation studies?

Clinical and experimental rheumatology·2026
Same journal

Comprehensive evaluation of bone structural and microarchitectural changes in rheumatoid arthritis treated with baricitinib using HR-pQCT, imaging, and biomarker analyses.

Clinical and experimental rheumatology·2026
Same journal

Tracking interstitial lung disease in systemic sclerosis: integrating lung magnetic resonance imaging into a clinically oriented multimodal follow-up strategy.

Clinical and experimental rheumatology·2026
See all related articles

Combination biologic therapies, including anti-tumor necrosis factor (anti-TNF alpha) agents, show promise for autoimmune diseases like rheumatoid arthritis. Targeted approaches may offer improved efficacy and reduced immunosuppression, with ongoing research exploring synergistic combinations.

Area of Science:

  • Immunology
  • Pharmacology
  • Rheumatology

Background:

  • Biologic therapies, including monoclonal antibodies and fusion proteins, represent genetically engineered treatments.
  • Anti-tumor necrosis factor (anti-TNF alpha) therapies have validated the potential of biologics in treating autoimmune diseases.
  • Current biologics target specific immune pathways to minimize generalized immunosuppression.

Purpose of the Study:

  • To review the potential of combination biologic therapy for rheumatoid arthritis and other autoimmune diseases.
  • To discuss the advantages and potential adverse effects of combining biologic agents.
  • To explore the synergy observed in animal models for re-induction of self-tolerance.

Main Methods:

  • Review of existing literature on biologic therapies and their mechanisms of action.

Related Experiment Videos

  • Analysis of data from animal models demonstrating synergistic effects of combination therapy.
  • Discussion of ongoing and anticipated clinical trials involving combination biologic treatments.

    • Main Results:

    • Targeted biologic therapies modulate specific immune aspects, reducing global immunosuppression.
    • Single-agent specificity may limit long-term disease control.
    • Animal models suggest therapeutic synergy with combination biologic approaches, particularly for inducing self-tolerance.

    Conclusions:

    • Combination biologic therapy holds significant potential for autoimmune diseases, potentially enhancing efficacy and tolerance induction.
    • Ongoing clinical studies are investigating combinations like anti-CD4 and TNF alpha blockade, and TNF alpha with interleukin-1 beta inhibitors.
    • Further research into immune regulation will likely drive the development of novel combination biologic strategies.